Cancer therapy, proteasome inhibitors

Adams J, Elliott PJ, Bouchard P (2004) Preclinical development of bortezomib (Vel-cade) Rationale for clinical studies. In Adams J (ed) Proteasome inhibitors in cancer therapy. Humana Press, Totowa, NJ, p 233... 

Adams J (2004) Proteasome inhibitors in cancer therapy. Human Press, New York... 

J. Adams, Proteasome Inhibitors in Cancer Therapy, Humana Press, Totowa, NJ, 2004. 

The ubiquitin-proteasome pathway has emerged as a major player in regnlating several important signaling processes such as cell proliferation and inflammation. As a result, proteasome inhibitors are being intensely pursued as both molecular probes of proteasome biology and as therapentic agents. Thus far, many proteasome inhibitors have been synthesized or isolated from natural sources, some of which are in clinical trial for cancer therapy. 

Bortezomib as a Proteasome Inhibitor for Cancer Therapy A Successful Example... 

Kobayashi and coworkers have applied this methodology to synthesize omuralide (207) (Scheme 7.70) [79], which is derived from the natural product lactacystin (204, Figure 7.4) and has been shown to be a selective inhibitor of the 20S proteasome found in mammahan and bacterial cells [80]. Proteasome inhibition has become an attractive and novel alternative therapy to cure cancer in recent years [81]. 

---